BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global
biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis,
President and Chief Executive Officer of Insmed, will present at the Deutsche Bank 43rd Annual Health Care Conference
in Boston, MA on Tuesday, May 8, 2018 at 4:10 p.m. EDT.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at
www.insmed.com. The webcast will be archived for a period of 90 days following the conclusion of
the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical Company focused on the unmet needs of patients with rare diseases. The
Company’s lead product candidate is ALIS, which is in late-state development for adult patients with treatment refractory NTM lung
disease caused by MAC, which is a rare and often chronic infection that is capable of causing irreversible lung damage and can be
fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1
with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information, visit www.insmed.com.
Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
